Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Beam Therapeutics (BEAM) over the last 5 years, with Dec 2024 value amounting to $108.9 million.

  • Beam Therapeutics' Current Deferred Revenue rose 23.50% to $110.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.3 million, marking a year-over-year increase of 23.50%. This contributed to the annual value of $108.9 million for FY2024, which is 39.05% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Current Deferred Revenue is $108.9 million, which was down 39.05% from $178.6 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Current Deferred Revenue peaked at $348.6 million during FY2021, and registered a low of $24,000 during FY2020.
  • In the last 3 years, Beam Therapeutics' Current Deferred Revenue had a median value of $178.6 million in 2023 and averaged $208.5 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 1,452,287.50% in 2021, then slumped by 47.19% in 2023.
  • Beam Therapeutics' Current Deferred Revenue (Yearly) stood at $24,000 in 2020, then soared by 1,452,287.50% to $348.6 million in 2021, then dropped by 2.99% to $338.2 million in 2022, then crashed by 47.19% to $178.6 million in 2023, then crashed by 39.05% to $108.9 million in 2024.